CEO Chip Davis’ abrupt departure from the Association for Accessible Medicines leaves the generics trade group in the unenviable position of looking for a new leader while it tries to make the most out of the election year drug pricing debate and also gears up to negotiate the renewal of user fees with the US FDA.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?